ESMO 2021 | Fractionated dose 177Lu-PSMA-617 in patients with mCRPC
Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York City, NY, presents the final results of the Phase I/II trial of fractionated dose 177Lu-PSMA-617 for patients with metastic castration-resistant prostate cancer (mCRPC). In this study, a single-cycle of fractionated-dose 177Lu-PSMA-617 was determined to be safe in patients with mCRPC. Despite no pre-selection for PSMA expression, most have post-treatment PSA decline with favorable biochemical and radiographic progression-free survival compared to historical non-PSMA controls and similar to PSMA-selected studies administering multiple cycles in a less dose-intense fashion. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Tagawa reports research support (to Weill Cornell since 2007) for Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma.
Dr Tagawa reports paid consultancy (since 2007) for Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, AIkido Pharma, Telix Pharma, Convergent Therapeutics.
Dr Tagawa reports unpaid consultancy for Atlab Pharma, Phosplatin Therapeutics, Amgen, Ambrx
